PA-824 is one of two nitroimidazoles in phase II clinical trials to treat tuberculosis. In mice, it has dose-dependent early bactericidal and sterilizing activity. In humans with tuberculosis, PA-824 demonstrated early bactericidal activity (EBA) at doses ranging from 200 to 1,200 mg per day, but no dose-response effect was observed. To better understand the relationship between drug exposure and effect, we performed a dose fractionation study in mice. Dose-ranging pharmacokinetic data were used to simulate drug exposure profiles. 
The development of new chemotherapeutic regimens capable of shortening the duration of tuberculosis (TB) treatment and/or improving the treatment of multidrug-resistant (MDR) TB is a major research objective (2) . PA-824 is one of two novel bicyclic nitroimidazoles in phase II clinical trials for TB treatment, the other being OPC-67683 (20) . PA-824 has potent in vitro activity against Mycobacterium tuberculosis, as evidenced by an MIC range of 0.015 to 0.25 g/ml, and retains this activity against isolates resistant to a variety of commonly used anti-TB drugs (30) . PA-824 is bactericidal against actively replicating bacilli, as well as nonreplicating bacilli under hypoxic or prolonged culture conditions (12, 17, 30) . However, the mechanism(s) by which it exerts its bactericidal effect have yet to be fully defined. Two potential mechanisms of action have been elucidated thus far. PA-824 inhibits synthesis of ketomycolates, an essential component of the mycobacterial cell wall (19, 30) . By analogy with other cell wall synthesis inhibitors, including isoniazid and ethionamide, this mechanism may explain bactericidal activity against actively multiplying bacilli but seems unlikely to explain activity against nonreplicating bacilli. The activity of PA-824 against slowly or nonreplicating bacilli was recently attributed to its capacity to donate nitric oxide during enzymatic nitroreduction within the tubercle bacillus and thereby poison the respiratory apparatus (19, 29) .
In murine models of TB, PA-824 has shown substantial dose-dependent bactericidal activity during both the initial phase of treatment and the continuation phase after 2 months of treatment with isoniazid, rifampin, and pyrazinamide (17, 32) . When PA-824 is administered alone as single daily doses, the minimal effective dose necessary for bacteriostatic activity is 12.5 mg/kg, and the minimal bactericidal dose (MBD) is 100 mg/kg (32) . When dosed daily at the MBD in combination with moxifloxacin and pyrazinamide, PA-824 contributes a sterilizing effect that is at least as strong as that of rifampin (24) . Furthermore, replacement of isoniazid with PA-824 in the standard first-line regimen of isoniazid, rifampin, and pyrazinamide results in more rapid culture conversion (23, 31) . These results in mice suggest PA-824 may have the potential to shorten the duration of treatment for drug-susceptible, as well as MDR, TB in humans. However, it became apparent during phase I testing that human dosing with the existing formulation would not attain the maximal serum concentration (C max ) or area under the serum concentration-time curve (AUC) observed in mice receiving 100 mg/kg, or even 50 mg/kg, once daily. Among healthy subjects receiving escalating daily doses of PA-824, near-maximal absorption was observed at the 600-mg dose, where the mean steady-state C max and AUC 0-were 3.8 g/ml and 70.4 g ⅐ h/ml, respectively, compared to values of 21.4 g/ml and 327.6 g ⅐ h/ml in mice receiving 100 mg/kg/day (8, 23) .
To better understand the relationship between drug expo-sure and effect, we undertook a dose fractionation study to determine the pharmacodynamic parameter most closely correlated with the anti-TB activity of PA-824 in mice and the magnitude of that parameter associated with bacteriostatic and bactericidal effects. In the meantime, the results of a doseranging, extended early bactericidal activity (EBA) trial in patients with smear-positive pulmonary TB have been reported (5) . In subjects receiving PA-824 once daily at doses of 200, 600, 1,000, and 1,200 mg for 14 consecutive days, substantial reduction of sputum CFU counts at a rate of ϳ0.1 log 10 CFU/ ml/day was observed at all doses tested (5) . In contrast to the dose-dependent activity of PA-824 observed in mice (32) , no dose-response was observed in the EBA trial (5) . The present pharmacodynamic study provides evidence that the favorable EBA of PA-824 and the lack of a dose-response effect in the EBA trial, when it may have been expected from the preceding experiments in mice, are due to the time-dependent nature of the relationship between drug exposure and its anti-TB effect.
MATERIALS AND METHODS
Bacterial strain. M. tuberculosis H37Rv was passaged in mice and frozen in aliquots at Ϫ80°C. After thawing, an aliquot was subcultured in Middlebrook 7H9 broth (Fisher, Pittsburgh, PA) with 10% oleic acid-albumin-dextrose-catalase (OADC; Difco, Detroit, MI) and 0.1% Tween 80 (Sigma, St. Louis, MO).
Antimicrobials. PA-824 was provided by the Global Alliance for TB Drug Development through RTI International (Research Triangle Park, NC). For administration to mice, PA-824 was suspended in a cyclodextrin micelle formulation (CM-2) as previously described (32) . A 50-mg/ml stock suspension was prepared and stored at 4°C. Aliquots were diluted with distilled water weekly to give the desired concentrations for dosing suspensions. Suspensions were shaken between doses to ensure uniform dosing.
Determination of the MIC. The MIC was determined by the agar proportion method (33) . Middlebrook 7H11 agar supplemented with 10% OADC and containing serial 2-fold concentrations of PA-824 ranging from 0.007 to 2.0 g/ml were inoculated with 0.5 ml of serial 100-fold dilutions of a log-phase broth culture of M. tuberculosis H37Rv with an optical density at 600 nm corresponding to ϳ10 8 CFU/ml. Drug-free and isoniazid-containing plates served as negative and positive controls, respectively. CFU were counted after 21 days incubation at 37°C with 5% ambient CO 2 . The MIC was defined as the lowest concentration at which the CFU count on drug-containing plates was Ͻ1% of the CFU count on drug-free plates.
Dose-ranging PK of PA-824. All procedures involving animals were approved by the institutional animal care and use committee. Single-dose pharmacokinetics (PK) of PA-824 in serum were evaluated in uninfected 6-week-old female BALB/c mice (Charles River, Wilmington, MA) after oral administration of 3, 10, 18, 30, 54, 96, 162, 243, 486, 729 , and 1,458 mg/kg doses. Multidose PK were also determined for 6-, 9.6-, 28.8-, 96-, and 192-mg/kg doses administered once daily for 5 days, with serum sampling performed after the fifth dose. In a second multidose PK study, mice received PA-824 at 192 mg/kg every 6 days, with serum sampling performed after the third dose. Mice had access to food and water ad libitum. PA-824 was administered by esophageal gavage. Three mice from each group were sacrificed at 0.5, 1, 2, 4, 8, 16, 24, 36, 48, 72, 96 , and 120 h after the last dose. Mice were anesthetized with isoflurane and exsanguinated by cardiac puncture. Blood was collected in microcentrifuge tubes and left at room temperature for 30 min before being centrifuged to harvest the serum. Serum samples were frozen at Ϫ80°C before the concentration of PA-824 was determined by a validated high-pressure liquid chromatography (HPLC) method (23) . Briefly, the concentration of PA-824 was determined with a system consisting of a ThermoFinnegan P4000 HPLC pump (San Jose, CA) with a model AS1000 fixed-volume autosampler, a model UV2000 UV detector, a Gateway series e computer (Poway, CA), and the Chromquest HPLC data management system. The plasma standard concentration curve for PA-824 ranged from 0.20 to 50 g/ml. The absolute recovery of PA-824 from plasma was 88.2%. The overall precision of the validation assay across all standards was 0.67 to 5.38%.
Serum concentration data were entered into a WinNonlin worksheet (WinNonlin version 4.0, 2002; Pharsight, Mountain View, CA) and analyzed by using standard noncompartmental and compartmental techniques in order to determine the relevant PK parameters for simulations. The serum concentration-time profile of each dosing regimen described in the dose fractionation protocol (Table 1) was modeled over a 6-day period to estimate the Cmax, the AUC 0-144 , and the T ϾMIC(0-144 h) for each regimen for free PA-824 concentrations, assuming 92.5% serum protein binding based on 93% protein binding in serum obtained from mice at the T max after a 25-mg/kg dose and up to 90% protein binding at a concentration of 3.6 g/ml in spiked mouse serum, as determined by equilibrium dialysis (TB Alliance, data on file). The AUC 0-24 was calculated by dividing the AUC 0-144 by 6.
Dose fractionation study. Six-week-old female BALB/c mice were infected by the aerosol route in the Inhalation Exposure System (Glas-Col, Inc., Terre Haute, IN) using a log-phase broth culture (optical density at 600 nm of ϳ0.8) with the expectation of implanting 3.5 log 10 CFU of M. tuberculosis H37Rv. Five mice were sacrificed the following day (day Ϫ13) to determine the number of CFU implanted in the lungs. Fourteen days after infection (day 0), five additional mice were sacrificed to determine the bacterial load at the start of treatment. The remaining animals were randomly distributed (three mice each) into 31 treatment groups. Treatment was administered by gavage for 24 consecutive days. During this time period, a total dosage of 0, 144, 288, 576, 768, 864, 1,152, 1,536, 1,728, 2,304, or 4,608 mg/kg was administered as 3, 4, 8, 12, 24, or 48 equally divided doses, as indicated in Table 1 . With the exception of 384 mg/kg administered every 6 days, individual doses did not exceed 288 mg/kg since the serum AUC did not increase in a dose-proportional fashion between 243 and Ն486 mg/kg. Mice were sacrificed 4 days after the final day of dosing to reduce the potential for drug carryover. Quantitative cultures were performed from lung homogenates using OADC-enriched 7H11 agar medium with selective antibiotics, as previously described (1, 23) . Lung CFU counts (x) were log transformed as log 10 (xϩ1) before analysis.
PD analyses. The data were analyzed with WinNonlin, Excel, and JMP statistical software (v.7.0.2; SAS Institute, Cary, NC). The data were corrected for a range of potential protein binding values (85 to 95%), and the resultant free drug concentrations were used to calculate pharmacodynamic (PD) parameters over 144 h (6 days). The relationships of these parameters to a range of potential MIC values (0.03125 to 0.25 g/ml) (30) were calculated. A series of exploratory models were analyzed in JMP statistical software. Finally, data were analyzed with four inhibitory E max and inhibitory sigmoid E max models (103, 104, 107, and 108) in WinNonLin, where E max is the maximum CFU count observed in the absence of drug (unabated growth). Model fit to the data was assessed using visual inspection of the y by x plots and by evaluating the variability (i.e., the percent coefficient of variation) in the parameter estimates, correlation analysis, and Akaike information criterion (AIC).
Human PK/PD simulations. Human phase I PK data were analyzed with noncompartmental methods and with a one-compartment open model with first order elimination, as well as a two-compartment model. On the basis of the AIC, the one-compartmental model resulted in a better fit of the data for each patient, as was the case in mice. Therefore, a one-compartment PK model was used to estimate the median PK parameter values and simulate the total and free PA-824 (assuming 5, 7, 10, or 15% unbound drug) concentrations at steady state for doses of 100, 200, and 400 mg of PA-824 daily. The free drug estimates were compared to MIC values ranging from 0.03125 to 0.25 g/ml (30) .
RESULTS

Determination of MIC.
The MIC of PA-824 against M. tuberculosis H37Rv was 0.06 g/ml. Single doses of PA-824 up to 1,456 mg/kg were well tolerated, with no adverse effects observed. Similarly, no untoward effect was observed in the multidose PK studies. The time to reach C max (T max ) in serum was 4.0 h. The elimination half-life was 4 to 6 h. PA-824 concentrations increased in a dose-proportional fashion over the dose range from 10 to 243 mg/kg (Fig. 1) . At doses of Ͼ486 mg/kg, the serum concentration-time profile suggested more complex PK behavior, possibly due to saturation of oral absorption. Also, late secondary and tertiary peaks at 24 and 48 h suggested precipitation and subsequent redissolution of PA-824 in the gastrointestinal tract, with diurnal variation. Hence, with the exception of 384 mg/kg administered every 6 days, individual dosing regimens in the dose fractionation study did not exceed 288 mg/kg. This dose range easily encompasses the achievable range of serum concentrations in humans with current oral formulations (8) .
Dose-response results. The mean lung CFU count on day Ϫ13 was 3.34 Ϯ 0.14 log 10 . At the start of the treatment on day 0, the mean lung CFU count was 6.30 Ϯ 0.10 log 10 . The final mean lung CFU count in untreated mice was 7.94 Ϯ 0.19 log 10 . Dose-dependent activity was observed with single daily doses ranging from 12.5 to 96 mg/kg (Fig. 2) . As observed in a previous experiment in which PA-824 was administered 5 days per week, the 12.5-mg/kg daily dose was associated with bacteriostasis, whereas 96 mg/kg was associated with a nearly 2-log 10 reduction in CFU counts compared to the day 0 count. No further significant reduction in CFU counts was observed with the dose increase from 96 to 192 mg/kg once daily.
Dose fractionation results. The maximum observed effect, a CFU reduction of 2.4 log 10 (or 0.1 log 10 CFU/day), was observed with twice daily administration of 96 mg/kg. Figure 3 shows the relationships between the log 10 CFU per lung at the end of treatment and the three primary descriptive PD parameters, assuming 7.5% free drug. Several models were tested, and we selected model 108, an inhibitory effect sigmoid E max model with a nonzero minimum for the lowest achievable log 10 CFU count. When modeled over a 6-day period, free drug T ϾMIC showed the best fit of the data (R 2 ϭ 0.87), where T ϾMIC is the cumulative percentage of the dosing interval that the drug concentration exceeds the MIC under steady-state pharmacokinetic conditions. A modest correlation was observed for fAUC/MIC (R 2 ϭ 0.60) and fC max /MIC showed little correlation (R 2 ϭ 0.17), where fAUC is the area under the concentration-time curve for the free, unbound fraction of a drug. The model 108 parameter estimates were as folows: E max , 7.94 log 10 CFU; 50% effective concentration (EC 50 ), 41.08% T ϾMIC ; E 0 , 3.06 log 10 CFU; and gamma, 1.06. Because it is an inhibitory model, E max is the maximum CFU count observed in the absence of drug (unabated growth), whereas E 0 is the model-predicted lowest achievable value for log 10 CFU count at the end of treatment. It should be noted that the model assumes that x is a continuous variable that could extend to infinity whereas, in this instance, T ϾMIC is a finite value capped at 100%. This limitation is not encountered with C max / MIC or AUC/MIC. The EC 50 (41.08%) is the T ϾMIC value associated with 50% of the maximum predicted effect, and gamma is the sigmoidicity factor describing the steepness of the curve.
At T ϾMIC of 100%, the model predicted 4.43 log 10 CFU remaining, which is 1.87 log 10 lower than the CFU count at the start of treatment (i.e., 6.30) and 3.51 log 10 lower than the CFU count in untreated mice (i.e., 7.94). The model predicted that 22% T ϾMIC is required for a bacteriostatic effect, 48% T ϾMIC is required for a 1-log 10 kill (compared to the CFU count at the start of treatment), and 77% T ϾMIC is required for a 1.59-log 10 kill (representing 80% of the maximum observed effect), respectively.
Within each dosing frequency, higher values for all three parameters were associated with greater kill. All regimens dosed every 144 h resulted in an increase in CFU counts, or in one case, bacteriostasis. When the regimens dosed every 144 h and every 72 h were successively removed from the model, the model fit of the parameters converged, and fAUC/MIC and T ϾMIC fit the data equally well: (i) for 12 
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Human pharmacodynamic simulations. PA-824 displayed favorable T ϾMIC values with doses as low as 100 mg once daily, depending on the assumptions for free drug and MIC (Table  2) . T ϾMIC values predictive of a bactericidal effect (i.e., Ն1-log reduction in CFU counts) were achieved with a 100-mg dose when the MIC was 0.03125 g/ml and were achieved when the MIC was 0.0625 g/ml as long as the percentage of free drug was Ն10%. A 200-mg dose produced better results, with bactericidal effects predicted against isolates for which the MIC was Ͻ0.1 g/ml (as in the recent EBA study [5] ), regardless of the free drug fraction, including 100% T ϾMIC observed with MIC values of 0.03125 g/ml and with an MIC of 0.0625 g/ml provided the percentage of free drug was Ն10%. A 400-mg dose reached 100% T ϾMIC with MIC values of Ͻ0.1 g/ml at any level of protein binding assessed.
DISCUSSION
PD analyses have played an increasingly important role in the development of new anti-infective drugs (3, 4, 22, 25) . Ideally, elucidation of the PD parameter most closely linked to a drug's antimicrobial effect and the magnitude of that parameter necessary for a given therapeutic effect enables the design of dosing regimens that optimize the odds of success without exposing patients to unnecessary toxicity (4, 22) . Animal models facilitate PD studies because drug exposures may incorporate a large range of drug exposures which are not suitable for clinical use (3) . Provided the animal model is relevant to the clinical condition, the results of PD analyses in animal models should inform the design and analysis of clinical trials, as well as clinical practice (3, 4, 11, 13, 22, 27) . Moreover, because the PD drivers are likely to be similar among members of a particular drug class, the information gained from the study of a single compound may be extrapolated to other compounds in development.
Since virtually all anti-TB drugs in regular clinical use were developed more than 40 years ago, there are few examples on which to assess the potential of PD studies in murine models to inform the clinical experience. However, the results with the two principal first-line agents, isoniazid and rifampin, have been promising. Jayaram et al. established AUC/MIC as the parameter most predictive of isoniazid's bactericidal effect (15) . A subsequent analysis of isoniazid PD demonstrated that the AUC/MIC value associated with 50% of the maximal effect was remarkably similar between the murine model, an in vitro hollow fiber model, and human EBA studies (7, 10) . Moreover, the EBA of isoniazid has been shown to plateau as the dose exceeds 300 mg in slow acetylators of the drug, for whom the AUC is expected to be approximately 20 to 25 g ⅐ h/ml, whereas doses greater than 600 mg may be necessary for maximal effect in rapid acetylators for whom the AUC after the 300-mg dose is approximately 6 to 8 g ⅐ h/ml (7, 27) . Similarly, Jayaram et al. found the AUC necessary for maximal isoniazid effect in mice to be 25 g ⅐ h/ml (15) . Thus, results in the murine model correlate well with isoniazid's effect in humans and define the exposure above which no additional therapeutic benefit is observed. Jayaram et al. also established AUC/MIC as the principal PD correlate of rifampin's bactericidal activity in mice (14) . Unlike the findings with isoniazid, the findings with rifampin clearly demonstrated that the currently recommended 600-mg human dose of rifampin produces an AUC that is at the low end of a steep dose-response curve and that increased rifampin doses beyond 600 mg should result in increased activity (14) . This observation is affirmed by results of EBA trials (6, 16) and provides support for exploring the efficacy, safety, and tolerability of higher rifamycin exposures (26, 28) .
In the present study, we performed a dose fractionation study in the murine model to describe the PD of PA-824, a promising new agent in phase II clinical trials for TB treatment. The results define free drug T ϾMIC as the parameter that correlates best with bactericidal activity and establish target values for bacteriostatic, bactericidal, and near-maximal bactericidal effects. The findings that (i) the regimens associated with the greatest reductions in log 10 CFU counts also had fAUC 0-144 /MIC values greater than 1,000 (or fAUC 0-24 /MIC values greater than 167) and (ii) the explanatory power of AUC/MIC was equal to that of T ϾMIC when the analysis was limited to regimens dosed every 48 h or less suggests that the magnitude with which free drug concentrations exceed the MIC also influences the bactericidal effect.
Importantly, the T ϾMIC target necessary for near-maximal bactericidal effects appears readily achievable in humans with daily PA-824 doses which have been safe and well tolerated in phase I studies (8, 9 ). This conclusion is strengthened by the results of a recent dose-ranging EBA trial in which PA-824 was found to have a substantial EBA of roughly 0.1 log 10 CFU/ml of sputum per day, but no difference in EBA was observed between the 200-, 600-, 1,000-, and 1,200-mg dose groups (5) . Although this finding may have been unexpected due to the dose-dependent nature of PA-824 with single daily doses in mice, the simplest explanation is that, due to the longer halflife of PA-824 in humans, the T ϾMIC target for near-maximal bactericidal effects was approached or attained in all human dose groups, whereas similar target attainment was not achieved in mice when single daily doses had similar AUC values but lower T ϾMIC values. Our simulations based on existing phase I PK data and MIC values from the EBA study suggest that this was indeed the case, since the T ϾMIC for the 200-mg dose is predicted to approach or attain the T ϾMIC target for near-maximal effect even if the free-drug fraction is assumed to be as low as 7% and to have substantial bactericidal effect even if the free drug fraction is as low as 5%. Interestingly, the average daily log CFU/ml reduction in the sputum of subjects in the EBA trial was 0.1, which is identical to the maximum observed effect in mice.
If the clinical results continue to follow the results in the murine model, our simulations suggest that a more typical dose-response relationship will be observed in an ongoing PA-824 EBA trial evaluating 50-, 100-, 150-, and 200-mg doses (A. Ginsberg, unpublished data). For example, lowering the dose from 200 to 100 mg may reduce the bactericidal effect, since 100 mg did not produce a meaningful T ϾMIC when the simulations were performed with our baseline assumptions of 5% free drug and MIC of 0.0625 g/ml (Table 2) . However, this analysis is very sensitive to the protein binding assumption. When the protein binding was assumed to be Յ90%, this dose produced a bactericidal T ϾMIC with MIC values of Յ0.0625 g/ml. Using the same set of assumptions, the 50-mg dose would not be expected to have significant bactericidal activity. Therefore, bacteriostatic or submaximal bactericidal effects may be expected at or below 100 mg. Regardless of its outcome, the above described, "low-dose" EBA trial provides an opportunity to reevaluate the correspondence between results in the murine model and those in human subjects.
The results and discussion presented here must be interpreted with several caveats in mind. First, our study assessed the PD of PA-824 against an acute infection in mice. As evidenced by a Ͼ1.5-log 10 increase in CFU counts among untreated mice over the duration of the treatment phase, the predominant bacterial population was in the logarithmic growth phase at the initiation of treatment. Thus, while the results and conclusions of the present study may correspond well with the outcomes of an EBA study, they may not apply to the activity of PA-824 against nonreplicating or slowly replicating bacterial subpopulations. Additional studies in animal models enriched for such "persisters" are under way to determine whether a similar PD relationship holds for bactericidal effects against these subpopulations. This question is of particular interest for PA-824 because at least two different mechanisms of action have been described (19, 29, 30) . For example, it is tempting to hypothesize that the time-dependent killing of actively multiplying bacilli observed in the present study results from inhibition of mycolic acid synthesis by PA-824 but that another mechanism, such as respiratory toxicity caused by reactive nitrogen intermediates, may drive the bactericidal activity against nonreplicating or slowly replicating bacilli according to a different PD relationship.
A second limitation of the present study relates to challenges inherent in estimating the impact of protein binding on the PD of highly bound drugs for which small changes in the estimate of the protein-bound fraction results in large changes in the free, biologically active fraction. Estimates of the T ϾMIC are particularly sensitive to such changes. Moreover, applying a single constant protein binding value across the range of drug concentrations and in vivo conditions, as we have done here, is certain to be overly simplistic. Other unmeasured factors, such as the kinetics of drug-protein interactions and the proportion of free drug in various tissues and the intracellular environment, may also contribute to the impact of protein binding in ways that cannot be modeled effectively. We have relied on plasma protein binding data from mice and from humans and presented analyses with differing protein binding constants in order to clearly represent the sensitivity of the model to changes in protein binding assumptions.
Our human PD simulations were based on data from healthy volunteers and not the subjects of the EBA trial. Although the (21) . Moreover, our simulations were deterministic in nature and did not specifically account for intersubject variation in the PK of PA-824 or the susceptibility of different bacterial isolates to PA-824. Future evaluations may include population PK data from TB patients and probabilistic PD models to further define the optimal doses of PA-824 for future clinical studies. Finally, we used a single M. tuberculosis strain in the present study. MacGowan et al. recently presented evidence that, among Staphylococcus aureus isolates exposed to moxifloxacin in vitro, the magnitude of the AUC/MIC associated with a targeted antimicrobial effect varies significantly and may affect target attainment rates and breakpoint selection (18) . Since M. tuberculosis is more highly conserved genetically than S. aureus, the variability may not be as significant. However, this issue warrants consideration in future studies.
In conclusion, PA-824 exhibited time-dependent bactericidal activity in a murine model of active TB with a maximal observed bactericidal effect of 0.1 log CFU/day over 24 days. fAUC/MIC also was a useful measure of PA-824 activity. This analysis supports, and is supported by, the findings of a recent dose-ranging EBA study in humans in which PA-824 resulted in a 0.1 log CFU/ml/day reduction in sputum over 14 days, with no dose-response relationship observed between 200 and 1200 mg, a range over which our PD simulations predict all dose groups would have approached or met the target T ϾMIC for maximal observed bactericidal effect. A dose-response effect and reduction in bactericidal activity is predicted for lower doses, beginning at 50 to 100 mg, depending on the protein binding assumption. If confirmed in the ongoing low-dose EBA trial, these results indicate that T ϾMIC , in conjunction with fAUC/MIC, is the parameter on which dose optimization of PA-824 should be based. Similar time-dependent PD are likely to be observed for OPC-67683 and other nitroimidazole derivatives with similar mechanisms of action. PD studies should be performed for new anti-TB drugs in development to aid compound and dose selection for preclinical studies and dose selection for clinical trials.
